Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD3 x anti-CD20 bispecific antibody
- Development stage
- Unknown
- Lead developer
- Barbara Ann Karmanos Cancer Institute
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The anti-CD3 x anti-CD20 bispecific antibody (CD20Bi) is a bispecific antibody designed to target both CD3 on T cells and CD20 on B cells. It is produced by chemically heteroconjugating the anti-CD20 monoclonal antibody rituximab with the anti-CD3 monoclonal antibody muromonab-CD3 (OKT3). CD20Bi is primarily used to arm ex vivo expanded autologous activated T cells (aATC) to create CD20Bi-armed activated T cells (CD20Bi-aATC), which are then infused back into patients to target and destroy CD20-expressing malignant cells. This approach has been evaluated in clinical trials for the treatment of non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) in combination with autologous stem cell transplantation (ASCT).
- Other names
- CD20 BATsCD-20 BATsCD 20 BATsCD20Bi aATCCD-20Bi aATCCD 20Bi aATCCD20Bi-activated T cellsCD-20Bi-activated T cellsCD 20Bi-activated T cellsCD20Bi-armed ATCCD-20Bi-armed ATCCD 20Bi-armed ATCCD20Bi-armed activated T cellsCD-20Bi-armed activated T cellsCD 20Bi-armed activated T cellsanti-CD3 x anti-CD20 bispecific antibody-armed activated T cellsanti-CD-3 x anti-CD20 bispecific antibody-armed activated T cellsanti-CD 3 x anti-CD20 bispecific antibody-armed activated T cells
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on anti-CD3 x anti-CD20 bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD3 x anti-CD20 bispecific antibody.